Thomas Powles, MBBS, MCRP, MD
Articles by Thomas Powles, MBBS, MCRP, MD
TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer
ByFunda Meric-Bernstam, MD,Christos Fountzilas,Izuma Nakayama,Takahiro Kogawa,Tomohiro Nishina,Thomas Powles, MBBS, MCRP, MD,Jin Won Kim,Yen-Yang Chen,Francois Ghiringhelli,Valentina Gambardella,James W. Smithy,Jérome Fayette,Fan Jin,Y.K. Chang,Kendall Sullivan,Sue Yueh,Ajlan Atasoy,Andrea Sporchia,Ragini Kudchadkar, MD,Hidetoshi Hayashi 
Key Advances Across Kidney Cancer Research and Management at KCRS 2025
ByThomas Powles, MBBS, MCRP, MD,David Braun, MD, PhD,Wenxin (Vincent) Xu, MD,Eric Jonasch, MD Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.
The Q-TWiST analysis from the LITESPARK-005 trial showed statistically significant improvement of belzutifan over everolimus in patients with clear cell RCC.
Results from a Q-TWiST analysis of the LITESPARK-005 trial showed a trend favoring belzutifan over everolimus for patients with clear cell RCC.
Dosing Lenvatinib for Treatment of Advanced Renal Cell Carcinoma
ByMehmet Asim Bilen, MD,Marie Carlo, MD,Robert J. Motzer, MD,Moshe Ornstein, MD, MA,Brian I. Rini, MD,Rana R. McKay, MD,Thomas Powles, MBBS, MCRP, MD Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.
The expert from Barts Cancer Centre in London discusses future directions for avelumab and the rapidly advancing field of urothelial cancer.
